LONDON (dpa-AFX Broker) - The British investment bank Barclays has lowered its target price for Merck KGaA from 205 to 195 euros, but left its rating at "Overweight". The surprising research setback for Xevinapant will weigh significantly on the shares of the Darmstadt-based company, wrote analyst Emily Field in her commentary on Monday evening. In her model, she assigns the cancer drug a net present value (NPV) of only two percent, but expects higher price discounts./ag/ajx

Publication of the original study: 24.06.2024 / 22:39 / GMT

First dissemination of the original study: 25.06.2024 / 03:00 / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------